IMMUNE GLOBULIN
IV infusion only
Cytomegalovirus Immune Globulin Intravenous (Human)

OTHER NAMES	CMV Ig, CMV immune globulin, CMV IGIV, Cytomegalovirus Immune Globulin Intravenous, Cytogam®
PRODUCT COMPOSITION	Cytogam® is a solvent detergent treated, clear, colourless solution fractionated from large human plasma pools using ethanol precipitation. It contains a relatively high concentration of IgG antibodies directed against Cytomegalovirus (CMV).
INFORMED CONSENT	Mandatory
ALTERNATIVES	**Non-blood Product:** None
	Blood Product: None
DOSAGE	Maximum recommended total dosage per infusion is 150mg Ig/kg • Within 72 hours of transplant: 150mg/kg • 2, 4, 6, and 8 weeks post transplant: 100mg/kg • 12 and 16 weeks post transplant: 50mg/kg
ADMINISTRATION	**Intravenously only.** Reaffirm product and rate with each treatment as per product monograph and in consideration of patient tolerance to rate of infusion. • Supplied to unit in a bottle or in a bag dependant on dosage • Should be inspected visually for particulate matter and discoloration prior to administration, do not infuse if it is cloudy, coloured, or has particulates • Must be administered using a 15 micron filter • Initial dose at 15mg Ig/kg body weight/hour for first 30 minutes. If no adverse reactions occur, rate may be increased to 30 mg Ig/kg/hr; if no adverse reactions occur after a subsequent 30 minutes, then the infusion may be increased to 60 mg Ig/kg/hr (volume not to exceed 75 mL/hour) • Subsequent doses at 15 mg Ig/kg/hr for 15 minutes. If no adverse reactions occur, increase to 30 mg Ig/kg/hr for 15 minutes and then increase to a **maximum** rate of 60 mg Ig/kg/hr (volume not to exceed 75 mL/hr) • Patient must be monitored closely during and after 3each rate change **Administer the entire amount**
DIAGNOSTIC MONITORING	**Vital sign monitoring as per hospital policy for any blood, blood component and other related product.** In the event of an immediate or suspected transfusion reaction, refer to hospital policy and procedures.
CLINICAL INDICATIONS	• CMV Ig is indicated for prevention of CMV disease in transplant recipients who are seronegative for CMV and who receive a transplant from a CMV seropositive donor.
SPECIAL CONSIDERATIONS	• TM will need approximately 30 minutes preparation time • IVIG is contraindicated in individuals with known anaphylactic or severe systemic response to human immune globulin. Individuals with severe, selective IgA deficiencies who have known antibody against IgA should only receive IVIg with utmost cautionary measure and when alternate treatments have failed • Product may interfere with the immune response to live virus vaccines such as measles, mumps, and rubella; vaccination with live virus vaccines should be deferred until 3mo after administration.
STORAGE CONDITIONS	Stored in a TM- monitored blood product storage refrigerator at 2-8˚C
REFERENCES	**Review product monograph**